Bedaquiline plus delamanid for XDR tuberculosis

The combination was initiated in a patient in whom an effective treatment cannot be designed, in the consideration that its potential life-saving benefits outweigh its unknown adverse event risks; in a department in which more than 100 tuberculosis cases a year are admitted to hospital, of which 14...

Full description

Bibliographic Details

Published in:	The Lancet infectious diseases Vol. 16; no. 3; p. 294
Main Authors:	Lachâtre, Marie, Rioux, Christophe, Dû, Damien Le, Fréchet-Jachym, Mathilde, Veziris, Nicolas, Bouvet, Elisabeth, Yazdanpanah, Yazdan
Format:	Journal Article
Language:	English
Published:	United States Elsevier Ltd 01.03.2016 Elsevier Limited
Subjects:	Antitubercular Agents - therapeutic use Diarylquinolines - therapeutic use Extensively Drug-Resistant Tuberculosis - drug therapy Extensively Drug-Resistant Tuberculosis - surgery Health Services Accessibility Humans Infectious Disease Infectious diseases Male Mycobacterium Nitroimidazoles - therapeutic use Oxazoles - therapeutic use Tuberculosis
ISSN:	1473-3099, 1474-4457, 1474-4457
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!